Hims & Hers Health (HIMS) Net Income towards Common Stockholders (2019 - 2026)
Hims & Hers Health's (HIMS) quarterly Net Income towards Common Stockholders came in at -$92.1 million in Q1 2026, down 286.15% year-on-year from $49.5 million in Q1 2025, and down 547.14% quarter-over-quarter from $20.6 million in Q4 2025.
Hims & Hers Health (HIMS) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Hims & Hers Health has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting -$92.1 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$92.1 million, down 286.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$13.2 million (down 108.05% YoY), and the FY2025 annual result was $128.4 million, up 1.85% from the prior year.
- Net Income towards Common Stockholders came in at -$92.1 million for Q1 2026 at Hims & Hers Health, down from $20.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $75.6 million in Q3 2024 to a low of -$92.1 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is $1.2 million (2023), against an average of $4.3 million.
- Across the five-year window, Net Income towards Common Stockholders soared 1990.36% in 2024 and plunged 286.15% in 2026, its largest moves.
- Hims & Hers Health's Net Income towards Common Stockholders stood at -$10.9 million in 2022, then soared by 111.41% to $1.2 million in 2023, then jumped by 1990.36% to $26.0 million in 2024, then declined by 20.84% to $20.6 million in 2025, then sank by 547.14% to -$92.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$92.1 million (Q1 2026), $20.6 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.12 Mn |
| Dec 31, 2025 | 20.60 Mn |
| Sep 30, 2025 | 15.77 Mn |
| Jun 30, 2025 | 42.51 Mn |
| Mar 31, 2025 | 49.49 Mn |
| Dec 31, 2024 | 26.03 Mn |
| Sep 30, 2024 | 75.59 Mn |
| Jun 30, 2024 | 13.30 Mn |
| Mar 31, 2024 | 11.13 Mn |
| Dec 31, 2023 | 1.25 Mn |
| Sep 30, 2023 | -7.57 Mn |
| Jun 30, 2023 | -7.16 Mn |
| Mar 31, 2023 | -10.07 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -18.84 Mn |
| Jun 30, 2022 | -19.68 Mn |
| Mar 31, 2022 | -16.25 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -15.94 Mn |
| Jun 30, 2021 | -9.15 Mn |